NMO Spectrum Disorder Clinical Trials

28 clinical trials for NMO Spectrum Disorder across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE) — RECRUITING
• Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) — RECRUITING · PHASE1
• Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD) — RECRUITING · NA
• Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study. — RECRUITING
• Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD — RECRUITING
• Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases — RECRUITING · PHASE1
• Biorepository and Registry for Plasma Exchange Patients — RECRUITING
• China National Registry of Neuro-Inflammatory Diseases — RECRUITING
• Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of RD06-04 in Patients With Active Autoimmune Diseases — WITHDRAWN · PHASE1
• Tongji NADs Cohort — NOT_YET_RECRUITING
• Multiple Sclerosis Versus Neuromyelitis Optica Spectrum Disorder — NOT_YET_RECRUITING
• A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders — WITHDRAWN · PHASE2
• Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders — ACTIVE_NOT_RECRUITING · PHASE2
• ACT with NMOSD Patients and Caregivers Pilot Study — COMPLETED · NA
• Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders — COMPLETED · PHASE1
• FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack — OTHER · PHASE2
• National, Multicentric Registry Study on Neuroimmunological Diseases in China — OTHER
• Pediatric NMOSD Observational Study — COMPLETED
• Epidemiological Characteristics of COVID-19 in Patients With MS or NMO — COMPLETED
• Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder — COMPLETED · PHASE4
• Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD) — COMPLETED · PHASE3
• Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) — COMPLETED · PHASE3
• A Study of LP-168 in Healthy Volunteers — COMPLETED · PHASE1
• Sensitivity and Specificity of TSA-CBA for Autoantibodies Against Neural Antigen Determination — OTHER
• A Study of HBM9161 in NMOSD Patients — COMPLETED · PHASE1
• Imaging Evaluation of Central Nervous Autoimmune Diseases — OTHER
• Autologous Transplant To End NMO Spectrum Disorder — WITHDRAWN · PHASE2

Refine this search